Overview

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Status:
Recruiting
Trial end date:
2027-12-06
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company